Ceruletide Inhibitor

Name: Ceruletide Inhibitor; MyBioSource
Brand: MyBioSource
SKU: MBS5754699
Availability: InStock
Rating: 5 (10 reviews)

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5754699

Ceruletide is a potent agonist of cholecystokinin receptor and it also is a safe and effective cholecystokinetic agent. It has a direct spasmogenic effect on the gallbladder muscle and bile ducts. More details

Please Inquire

Product Documentation

Sample Manual Insert View PDF

Testing Data View PDF

Certificate of Analysis (COA) View PDF

QC Report View PDF

Material Safety Data Sheet View PDF

Technical Datasheet View PDF

Protocol View PDF

Product Overview

Online Datasheet in PDF

Product Name

Ceruletide, Inhibitor

Full Product Name

Ceruletide

Product Synonym Names

Caerulein; Cerulein; FI-6934

Form/Format

Solid. Powder

Purity/Purification

99.54%

Preparation and Storage

Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent

Molecular Weight

1352.41

Solubility

H2O: 100mg/mL (73.94mM)
DMSO: 96mg/mL (70.98mM)
(<1mg/ml refers to the product slightly soluble or insoluble)

Formula

C58H73N13O21S2

SMILES

NC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCSC)NC(=O)[C@H](Cc3cnc2ccccc23)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](Cc4ccc(OS(=O)(=O)O)cc4)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](NC(=O)[C@@H]5CCC(=O)N5)CCC(N)=O)[C@@H](C)O

CAS Number

17650-98-5

Target & IC50

Cholecystokinin receptor

In Vitro

Ceruletide (5-15ng/kg, i.v.) shows a marked spasmogenic effect on the pylorus of rats. Ceruletide also reduces blood pressure in anesthetized dogs [1]. Ceruletide (0.4-0.5 mcg/kg, i.v.; 3-4 mcg/kg, s.c.) results in emesis and evacuation of the bowel in the intact conscious dog, and recovery is complete 15-30 min after i. v. administration and 2-4 hr after s.c. administration. Ceruletide SBA stimulation may perform as well as PP SBA stimulation in dogs with the portosystemic shunt and be more sensitive for the detection of hepatic dysfunction in dogs with the upper respiratory disease [3].

Product Categories/Family for Ceruletide, inhibitor

GPCR/G Protein

Product References and Citations for Ceruletide, inhibitor

Vincent ME, et al. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.
Vincent ME, et al. Pharmacology, clinical uses, and adverse effects of ceruletide, a cholecystokinetic agent. Pharmacotherapy. 1982 Jul-Aug;2(4):223-34.
Bridger N, et al. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
Bridger N, et al. Comparison of postprandial and ceruletide serum bile acid stimulation in dogs. J Vet Intern Med. 2008 Jul-Aug;22(4):873-8.
Steinle AU, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30.
Steinle AU, et al. NF-kappaB/Rel activation in cerulein pancreatitis. Gastroenterology. 1999 Feb;116(2):420-30.
Zarrindast MR, et al. Effects of cholecystokinin receptor agonist and antagonists on morphin dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4.
Zarrindast MR, et al. Effects of cholecystokinin receptor agonist and antagonists on morphin dependence in mice. Pharmacol Toxicol. 1995 Dec;77(6):360-4.

Other Notes

Small volumes of Ceruletide, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ceruletide purchase

MBS5754699 is an inhibitor targeting Ceruletide.